Patents by Inventor Hyea Kyung Ahn
Hyea Kyung Ahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092913Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: November 17, 2023Publication date: March 21, 2024Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
-
Publication number: 20240059768Abstract: The present invention relates to a stable ophthalmic composition comprising tanfanercept, which does not use a stabilizer, and methods of preparing and using the composition. According to the present invention, it was found that the use of a stabilizer such as histidine or sucrose causes the generation of impurities such as tanfanercept-derived acidic/basic variants, and affects biological activity. The ophthalmic pharmaceutical composition according to the present invention may control pH rather than excluding the use of such a stabilizer to significantly reduce the generation of impurities under not only a refrigerated storage condition but also accelerated conditions and a stress condition, thereby preparing a stable tanfanercept ophthalmic composition.Type: ApplicationFiled: January 13, 2022Publication date: February 22, 2024Inventors: Seung Kook Park, Hyea Kyung Ahn, Mi Jin Jung, Hye Eun Shim
-
Publication number: 20240059767Abstract: The present invention relates to treatment of dry eye syndrome using a tanfanercept-containing ophthalmic composition. According to the present invention, as a result of clinical trial on dry eye syndrome, the tanfanercept-containing ophthalmic composition demonstrated excellent effects with regard to improvement of a central corneal staining score (CCSS) and a total corneal staining score (TCSS), which is clinically important. Further, such improvement of a central corneal staining score (CCSS) and a total corneal staining score (TCSS) was more significantly demonstrated in the patients with moderate-to-severe severity of dry eye. In addition, the patients with higher ocular discomfort score or higher eye dryness score, which are subjective symptoms, also showed greater improvement. Even though the same dose of tanfanercept was used, the tanfanercept-containing ophthalmic composition showed superior efficacy in the patient having more serious or severe baseline sign or symptom scores.Type: ApplicationFiled: January 14, 2021Publication date: February 22, 2024Inventors: Seung Kook Park, Hyea Kyung Ahn, Hye Eun Shim, Young Ju Kim, Sun Mi Park, Joo Hyun Chae
-
Publication number: 20230235063Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: February 21, 2023Publication date: July 27, 2023Applicant: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Patent number: 11613578Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: GrantFiled: December 11, 2019Date of Patent: March 28, 2023Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Publication number: 20200109201Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: December 11, 2019Publication date: April 9, 2020Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
-
Patent number: 10544226Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: GrantFiled: April 30, 2015Date of Patent: January 28, 2020Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Patent number: 10336825Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: GrantFiled: April 5, 2017Date of Patent: July 2, 2019Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Publication number: 20190135917Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: January 15, 2019Publication date: May 9, 2019Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
-
Publication number: 20170210805Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: April 5, 2017Publication date: July 27, 2017Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Publication number: 20170210801Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: April 30, 2015Publication date: July 27, 2017Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Patent number: 9580490Abstract: The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF? neutralizing activity, and inhibits TNF? activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.Type: GrantFiled: February 7, 2013Date of Patent: February 28, 2017Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Yeon Jung Song, Eun Sun Kim, Hyea Kyung Ahn, Jae Kap Jeong, Hung Keun Lee
-
Publication number: 20150119338Abstract: The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF? neutralizing activity, and inhibits TNF? activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.Type: ApplicationFiled: February 7, 2013Publication date: April 30, 2015Inventors: Sung Wuk Kim, Seung Kook Park, Yeon Jung Song, Eun Sun Kim, Hyea Kyung Ahn, Jae Kap Jeong, Hung Keun Lee
-
Publication number: 20070264710Abstract: Disclosed is a process for producing a human thrombopoietin (hTPO)-containing culture fluid, comprising the step of culturing a eukaryotic cell expressing hTPO in a serum-free medium that contains a negligible amount of serum. In addition, the present invention discloses a process for purifying hTPO from a hTPO-containing biological fluid, comprising the steps of (a) subjecting the biological fluid to affinity chromatography; (b) subjecting an eluate obtained at step (a) to hydrophobic interaction chromatography; (c) subjecting an eluate obtained at step (b) to reverse phased chromatography; and (d) subjecting an eluate obtained at step (c) to anion exchange chromatography. In addition, the present invention discloses hTPO with a high sialic acid content obtained by the process which comprises the step of loading, the eluate obtained at step (c) onto an ionic exchange chromatography column and collecting hTPO with a high content of sialic acid eluted selectively from the column by a 0.15-0.Type: ApplicationFiled: October 9, 2003Publication date: November 15, 2007Inventors: Hyea-Kyung Ahn, Joo-Young Chung, Young-Ju Cho, Tae-Soo Kim, Yeo-Wook Koh, Seung-Wook Lim, Yeon-Joo Hong
-
Patent number: 7037491Abstract: The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.Type: GrantFiled: January 26, 2005Date of Patent: May 2, 2006Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Joo Young Chung, Sang Kyu Park, Sang Myoung Ju, Hyea Kyung Ahn, Seung Wook Lim, Woo Ik Chang, Seung Kook Park, Yeo Wook Koh, Ji Soo Park
-
Publication number: 20030228666Abstract: The present invention relates to novel human thrombopoietin (; hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.Type: ApplicationFiled: May 20, 2003Publication date: December 11, 2003Applicant: Daewoong Pharmaceutical Co., Ltd.Inventors: Joo Young Chung, Sang Kyu Park, Sang Myoung Ju, Hyea Kyung Ahn, Seung Wook Lim, Woo Ik Chang, Seung Kook Park, Yeo Wook Koh, Ji Soo Park